Csenge Advisory Group cut its holdings in shares of Allergan plc (NYSE:AGN) by 16.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,231 shares of the company’s stock after selling 235 shares during the period. Csenge Advisory Group’s holdings in Allergan were worth $235,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State Street Corp lifted its stake in Allergan by 12.9% during the third quarter. State Street Corp now owns 14,814,455 shares of the company’s stock worth $2,493,128,000 after purchasing an additional 1,696,205 shares during the last quarter. Third Point LLC bought a new stake in Allergan during the third quarter worth $605,844,000. Assenagon Asset Management S.A. lifted its stake in Allergan by 415.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,777,375 shares of the company’s stock worth $299,114,000 after purchasing an additional 1,432,555 shares during the last quarter. Boussard & Gavaudan Investment Management LLP bought a new stake in Allergan during the third quarter worth $219,436,000. Finally, Sachem Head Capital Management LP bought a new stake in Allergan during the third quarter worth $212,887,000. Hedge funds and other institutional investors own 81.61% of the company’s stock.
Several equities research analysts have weighed in on the company. SunTrust Banks upped their target price on Allergan from $194.00 to $202.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group cut Allergan from a “buy” rating to a “neutral” rating and increased their price target for the company from $189.00 to $203.00 in a research note on Tuesday, November 19th. ValuEngine cut Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Co cut Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 price target for the company. in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and three have assigned a buy rating to the company’s stock. Allergan has a consensus rating of “Hold” and a consensus target price of $178.72.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Monday, February 10th. The company reported $5.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.57 by $0.65. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 9.75% and a negative net margin of 32.76%. Allergan’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the business posted $4.29 earnings per share. Research analysts expect that Allergan plc will post 16.98 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Friday, February 14th will be issued a $0.74 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.46%. Allergan’s payout ratio is 16.78%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: Different Types of Derivatives
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.